15
ASCO Resource Levels
Strength of
Recommendation Basic Limited Enhanced Maximal
N/A N/A N/A Immune
checkpoint
inhibitors
a
Moderate
N/A N/A Doublet
chemotherapy
Doublet
chemotherapy
± anti-VEGF
(bevacizumab)
Strong
(chemotherapy)
Moderate
(chemotherapy +
anti-VEGF)
N/A N/A May offer
triplet
chemotherapy
May offer triplet
chemotherapy
± anti-VEGF
(bevacizumab)
Strong
(chemotherapy)
Moderate
(chemotherapy +
anti-VEGF)
N/A Single agent
fluoropyrimidine
Single agent
fluoropyrimidine
± anti-VEGF
(bevacizumab)
Strong
(chemotherapy)
Moderate
(chemotherapy +
anti-VEGF)
Discontinue
oxaliplatin aer a
period of induction
if stable disease
or response;
maintenance
single agent
fluoropyrimidine ±
anti-VEGF therapy;
if progression, then
reintroduce the
first-line therapy or a
second-line therapy
Moderate
Doublet irinotecan-based
chemotherapy
Strong
Follow Recommendations in Table 5
